
Yao Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6870462/publications.pdf Version: 2024-02-01



YAO MANG

#	Article	IF	CITATIONS
1	Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science, 2020, 368, .	12.6	716
2	Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia. Molecular Therapy, 2015, 23, 184-191.	8.2	318
3	Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clinical Cancer Research, 2017, 23, 1156-1166.	7.0	275
4	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Science China Life Sciences, 2016, 59, 468-479.	4.9	222
5	CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncolmmunology, 2018, 7, e1440169.	4.6	219
6	Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. Journal of the National Cancer Institute, 2016, 108, .	6.3	212
7	Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein and Cell, 2018, 9, 838-847.	11.0	196
8	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2020, 13, 30.	17.0	187
9	Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. Journal of Hematology and Oncology, 2017, 10, 4.	17.0	160
10	Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clinical Cancer Research, 2018, 24, 1277-1286.	7.0	159
11	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clinical Immunology, 2014, 155, 160-175.	3.2	156
12	Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncolmmunology, 2015, 4, e1027469.	4.6	142
13	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood, 2020, 136, 1632-1644.	1.4	119
14	Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduction and Targeted Therapy, 2016, 1, 16002.	17.1	110
15	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nature Communications, 2021, 12, 409.	12.8	109
16	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. Journal of Hematology and Oncology, 2019, 12, 128.	17.0	106
17	Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein and Cell, 2018, 9, 867-878.	11.0	81
18	Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. Cytotherapy, 2020, 22, 573-580.	0.7	77

YAO WANG

#	Article	IF	CITATIONS
19	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. , 2019, 7, 209.		73
20	Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2016, 9, 131.	17.0	60
21	GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget, 2017, 8, 11788-11796.	1.8	53
22	Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report. Journal of Immunology Research, 2014, 2014, 1-14.	2.2	52
23	Clinical development of CAR T cell therapy in China: 2020 update. Cellular and Molecular Immunology, 2021, 18, 792-804.	10.5	50
24	Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. Protein and Cell, 2018, 9, 516-526.	11.0	46
25	Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. Journal of Hematology and Oncology, 2019, 12, 57.	17.0	46
26	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial. Leukemia, 2022, 36, 189-196.	7.2	45
27	CIK cells from recurrent or refractory AML patients can be efficiently expanded inÂvitro and used for reduction of leukemic blasts inÂvivo. Experimental Hematology, 2013, 41, 241-252.e3.	0.4	33
28	A unified model of the hierarchical and stochastic theories of gastric cancer. British Journal of Cancer, 2017, 116, 973-989.	6.4	33
29	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. Journal of Immunology Research, 2016, 2016, 1-11.	2.2	32
30	Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Journal of Genetics and Genomics, 2019, 46, 367-377.	3.9	29
31	Relationship between postoperative lordosis distribution index and adjacent segment disease following L4-S1 posterior lumbar interbody fusion. Journal of Orthopaedic Surgery and Research, 2020, 15, 129.	2.3	27
32	Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy. Clinical and Developmental Immunology, 2013, 2013, 1-12.	3.3	26
33	Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. Cellular and Molecular Immunology, 2020, 17, 430-432.	10.5	26
34	The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. Oncolmmunology, 2017, 6, e1323619.	4.6	23
35	Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. Journal of Hematology and Oncology, 2021, 14, 106.	17.0	22
36	Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells. Clinical and Developmental Immunology, 2011, 2011, 1-9.	3.3	20

YAO WANG

#	Article	IF	CITATIONS
37	CD58 loss in tumor cells confers functional impairment of CAR TÂcells. Blood Advances, 2022, 6, 5844-5856.	5.2	20
38	An LRP16-containing preassembly complex contributes to NF-κB activation induced by DNA double-strand breaks. Nucleic Acids Research, 2015, 43, 3167-3179.	14.5	19
39	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduction and Targeted Therapy, 2022, 7, 98.	17.1	19
40	Mutant B2Mâ€HLAâ€E and B2Mâ€HLAâ€G fusion proteins protects universal chimeric antigen receptorâ€modifie T cells from allogeneic NK cellâ€mediated lysis. European Journal of Immunology, 2021, 51, 2513-2521.	d _{2.9}	15
41	An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Science China Life Sciences, 2016, 59, 379-385.	4.9	14
42	Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduction and Targeted Therapy, 2017, 2, 17054.	17.1	14
43	The Role of Intraoperative Transesophageal Echocardiography in Robotic Mitral Valve Repair. Echocardiography, 2011, 28, 85-91.	0.9	13
44	Adaptive T cell immunotherapy in cancer. Science China Life Sciences, 2021, 64, 363-371.	4.9	13
45	CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. Blood Advances, 2022, 6, 2695-2699.	5.2	11
46	Chimeric antigen receptor modified T ells for cancer treatment. Chronic Diseases and Translational Medicine, 2018, 4, 225-243.	1.2	10
47	Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. Gene Therapy, 2018, 25, 198-204.	4.5	8
48	Inducing immunogenic cell death in immuno-oncological therapies. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 1-10.	2.2	8
49	Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092760.	3.2	7
50	Optimal Timing of Surgical Revascularization for Myocardial Infarction and Left Ventricular Dysfunction. Chinese Medical Journal, 2017, 130, 392-397.	2.3	6
51	Ankylosing spondylitis kyphosis surgical correction postoperative evaluation via SRS-22 domain investigation. Journal of Orthopaedic Surgery and Research, 2018, 13, 5.	2.3	6
52	Comparison of loss of correction between PSO and VCD technique in treating thoracolumbar kyphosis secondary to ankylosing spondylitis, a minimum 2 years follow-up. Journal of Orthopaedic Surgery and Research, 2019, 14, 137.	2.3	6
53	Robotic mitral valve repair: 7-year surgical experience and mid-term follow-up results. Journal of Cardiovascular Surgery, 2019, 60, 406-412.	0.6	6
54	Early clinical outcomes of thoracoscopic mitral valvuloplasty: a clinical experience of 100 consecutive cases. Cardiovascular Diagnosis and Therapy, 2020, 10, 841-848.	1.7	6

YAO WANG

#	Article	IF	CITATIONS
55	Imaging of Sodium MRI for Therapy Evaluation of Brain Metastase with Cyberknife at 7T: A Case Report. Cureus, 2018, 10, e2502.	0.5	6
56	Transesophageal echocardiography guided cannulation for peripheral cardiopulmonary bypass during robotic cardiac surgery. Chinese Medical Journal, 2012, 125, 3236-9.	2.3	6
57	Proper detailed parameters for S1 sacral alar iliac screw placement in the Chinese population, a 3D imaging study. Journal of Orthopaedic Surgery and Research, 2018, 13, 39.	2.3	5
58	Pedicle Subtraction Osteotomy with a Cage Prevents Sagittal Translation in the Correction of Kyphosis in Ankylosing Spondylitis. Chinese Medical Journal, 2018, 131, 200-206.	2.3	5
59	Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy, 2018, 20, 1155-1163.	0.7	5
60	Left atrial appendage exclusion is effective in reducing postoperative stroke after mitral valve replacement. Journal of Cardiac Surgery, 2020, 35, 3395-3402.	0.7	5
61	Long-Term Outcome of Intra-Myocardial Injection of Autologous Bone Marrow Mononuclear Cells Combined with Isolated Coronary Artery Bypass Grafting for Patients with Chronic Ischemic Heart Failure. Heart Surgery Forum, 2016, 19, 131.	0.5	5
62	Primary Lymphoma of the Heart: A Case Report of Surgical Treatment and Review of the Literature. Heart Surgery Forum, 2019, 22, E225-E228.	0.5	5
63	Effects of Surgical Ventricular Restoration on Left Ventricular Shape, Size, and Function for Left Ventricular Anterior Aneurysm. Chinese Medical Journal, 2017, 130, 1429-1434.	2.3	4
64	Echocardiographic Follow-up of Robotic Mitral Valve Repair for Mitral Regurgitation due to Degenerative Disease. Chinese Medical Journal, 2016, 129, 2199-2203.	2.3	4
65	Surgical effect and long-term clinical outcomes of robotic mitral valve replacement: 10-year follow-up study. Journal of Cardiovascular Surgery, 2021, 62, 162-168.	0.6	3
66	Congenital Giant Right Atrial Aneurysm: Echocardiographic Diagnosis and Surgical Management. Heart Surgery Forum, 2017, 20, 055.	0.5	2
67	Determination of multiple vitamins in 178 patients undergoing chemotherapy for lung cancer. Archives of Medical Science, 2021, , .	0.9	0
68	Neoadjuvant chemoradiotherapy combined with surgery in the treatment of potentially operable thoracic squamous cell carcinoma of the esophagus(ChiCTR-OIC-17011648): A phase II single center clinical study Journal of Clinical Oncology, 2019, 37, e15543-e15543.	1.6	0
69	Establishment of a chronic left ventricular aneurysm model in rabbit. Journal of Geriatric Cardiology, 2014, 11, 158-62.	0.2	0
70	769â€CAR T cells undergoing epigenetic reprogramming by low-dose decitabine enhances persistent anti-tumor efficacy in vivo. , 2020, , .		0
71	Ultrasound-guided cannulation of the internal jugular vein in robotic cardiac surgery. Chinese Medical Journal, 2013, 126, 2414-7.	2.3	0